Cargando…
1963. PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas Independent of Treatment as Prevention (2012–2017)
BACKGROUND: Tenofovir/Emtricitabine (TVD) was approved for a Pre-exposure Prophylaxis (PrEP) indication in the United States in July 2012. Biomedical HIV prevention tools can impact the rate of new HIV diagnoses but their relative contributions have not been described. METHODS: The analysis utilized...
Autores principales: | Mera-Giler, Robertino M, Das, Moupali, Hawkins, Trevor, Magnuson, David, Asubonteng, Julius, McCallister, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808906/ http://dx.doi.org/10.1093/ofid/ofz359.140 |
Ejemplares similares
-
Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
por: Mera, Robertino, et al.
Publicado: (2019) -
866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies
por: Liu, Albert, et al.
Publicado: (2021) -
1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019) -
995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020) -
1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)